Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years

    August 21, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

    August 21, 2026
    Facebook X (Twitter) Instagram
    Pro KhaleejPro Khaleej
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Pro KhaleejPro Khaleej
    Home » Envision Pharma Group Appoints Industry Leader Tino Quintero as General Manager/VP of Market Access & Customer Insights
    Featured News

    Envision Pharma Group Appoints Industry Leader Tino Quintero as General Manager/VP of Market Access & Customer Insights

    May 2, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    PHILADELPHIA, PA / ACCESSWIRE / May 1, 2023 / Envision Pharma Group (Envision) has appointed Tino Quintero to the role of General Manager/VP of Market Access & Customer Insights.

    Tino will be responsible for collectively driving Envision’s capability building, client and business development, client servicing, and project execution, as well as staff development and mentorship for the Market Access & Customer Insights teams.

    Meg Heim, CEO of Envision Pharma Group, shares, “I am so excited to welcome Tino to the Envision team as General Manager/VP of Market Access & Customer Insights. Tino’s depth of expertise and proven leadership capabilities in market access will drive Envision’s market access strategy as we continue to solidify our leadership and proficiency in the value and access and data analytics space. Tino will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

    Tino has over 25 years of demonstrated success as a biopharma and life sciences executive. He possesses broad experience in global commercial strategy, market and value access, and business development at Sarepta Therapeutics, Gilead, Vertex, AbbVie, and Syneos. He has been instrumental in the launch and commercialization of numerous products in various therapeutic areas, including cell and gene therapy, rare diseases, oncology, and infectious and autoimmune diseases. He has a consistent and proven track record of success in building, leading, and executing corporate goals.

    Tino joins Envision from The Q Group, where, as a founder, he advised executive leaders on critical operational and strategic areas for cell and gene therapy, mental health, and healthcare software companies. Prior to this, he was Chief Commercial Officer at Locus Biosciences where he led commercial strategy for the company’s early-stage pipeline assets, human resources, and strategic partnerships. Tino developed a go-to-market plan to secure Series B fundraising, corporate strategic leadership, and management of alliance partnerships.

    Tino adds, “I am very fortunate to join the Envision Pharma Group team during this exciting time of growth. We are leveraging data, technology, and our teams’ experience to address customers’ needs and improve outcomes. I look forward to accelerating our current business while expanding into new markets and engaging new customers.”

    About Envision Pharma Group

    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information:

    Colleen Carter
    Associate Director, Communications, Office of the CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    .

    Envision Pharma Group Appoints Industry Leader Tino Quintero as General Manager/VP of Market Access & Customer Insights

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    SOUEAST UAE launches S08 Luxury following the success of the Flagship S08DM

    August 19, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    August 7, 2026

    Risk-On or Risk-Off? How to Read Global Sentiment Before You Trade

    July 20, 2026

    Bond Yields Are Moving FX More Than Headlines – Here’s Why

    July 13, 2026

    Tamchy Special Financial Investment Territory on Issyk-Kul Launched in Kyrgyzstan

    July 6, 2026
    Latest News
    Business

    Wall Street rises after Treasury expands debt buybacks

    August 20, 2026

    U.S. stocks ended modestly higher Wednesday as long-term Treasury yields fell sharply. The S&P 500 rose 16.22 points, or 0.21%, to 7,707.98, ending a three-session losing streak. The Dow Jones Industrial Average gained 119.65 points, or 0.22%, to close at 53,463.05. The Nasdaq Composite added 41.38 points, or 0.16%, finishing at 26,331.09. Falling government bond yields helped major indexes recover after several sessions of pressure from rising borrowing costs. Bond prices climbed after the U.S. Treasury Department announced larger liquidity support buybacks for longer-dated government debt. Starting September 9, the maximum purchase size will increase from $2 billion to at least $4 billion per operation. The change covers nominal coupon securities in the 10-to-20-year and 20-to-30-year maturity sectors. The increased amounts will remain in effect through November 4. The department said strong volumes of high-quality offers supported the decision to increase liquidity operations in those sectors. Treasury yields moved lower following the announcement, reversing part of a recent rise in long-term borrowing costs. The 10-year Treasury yield fell to about 4.65%, while the 30-year yield declined to about 5.20%. The 30-year yield had reached 5.337% on Tuesday, its highest level since 2007. Bond yields move invers

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026
    © 2026 Pro Khaleej | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.